

West Virginia Bureau for Medical Services

Preferred Drug List (PDL) Changes

Pharmaceutical and Therapeutics (P&T) Committee Meeting Date: April 23, 2025

PDL Changes Effective Date: July 1, 2025

Effective July 1, 2025, the following changes will be made to the PDL pending recommendation and/or approval by the P&T Committee, the Bureau for Medical Services (BMS), and the West Virginia Department of Human Services (DoHS) Secretary.

For a comprehensive PDL, please visit the BMS website:

<https://dhhr.wv.gov/bms/BMS%20Pharmacy/Pages/Preferred-Drug-List.aspx>

NEW PREFERRED DRUGS

Therapeutic Class	Recommended for Non-Preferred Status
CYTOKINE AND CAM ANTAGONISTS	PYZCHIVA (ustekinumab-ttwe)
OBSTRUCTIVE SLEEP APNEA AGENTS	ZEPBOUND (tirzepatide)

NEW NON-PREFERRED DRUGS

Therapeutic Class	Recommended for Non-Preferred Status
ANDROGENIC AGENTS	AZMIRO (testosterone cypionate) injection
ANTIHEMOPHILIA AGENTS	ALHEMO (concizumab-mtci)
ANTIPSYCHOTICS, ATYPICAL AND COMBINATION	OPIPZA (aripiprazole) film, soluble
CYTOKINE AND CAM ANTAGONISTS	OTULFI (ustekinumab-aaaz)
CYTOKINE AND CAM ANTAGONISTS	SELARSDI ((ustekinumab-aekn)
CYTOKINE AND CAM ANTAGONISTS	STEQEYMA (ustekinumab-stba)
CYTOKINE AND CAM ANTAGONISTS	YESINTEK (ustekinumab-kfce)
IMMUNOMODULATORS, ATOPIC DERMATITIS	NEMLUVIO (nemolizumab-ilto) injection, powder
LIPOTROPICS, OTHER (NON-STATINS)	TRYNGOLZA (olezarsen)